Study shows complement activation marker C3dg, MASP-1, and MASP-3 levels before tumor necrosis factor inhibitor therapy predicted new bone formation after 2 years of follow-up among axial spondyloarthritis patients with a high risk of radiographic progression.
Could a single infusion transform a patient’s own T cells into cancer-fighting machines? Researchers are betting on single-stranded DNA and lipid nanoparticles to make in vivo CAR-T a scalable reality.
The American Cancer Society’s updated cervical cancer screening guideline introduces FDA-approved self-collected HPV testing and clearer exit criteria.